Herpes Simplex Infections - Pipeline Review, H2 2014

Published: Sep, 2014 | Pages: 140 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Herpes Simplex Infections - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Herpes Simplex Infections - Pipeline Review, H2 2014', provides an overview of the Herpes Simplex Infections's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Herpes Simplex Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Herpes Simplex Infections and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Herpes Simplex Infections
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Herpes Simplex Infections and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Herpes Simplex Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Herpes Simplex Infections pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Herpes Simplex Infections
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Herpes Simplex Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 7
Global Markets Direct Report Coverage 7
Herpes Simplex Infections Overview 8
Therapeutics Development 9
Pipeline Products for Herpes Simplex Infections - Overview 9
Pipeline Products for Herpes Simplex Infections - Comparative Analysis 10
Herpes Simplex Infections - Therapeutics under Development by Companies 11
Herpes Simplex Infections - Therapeutics under Investigation by Universities/Institutes 14
Herpes Simplex Infections - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Herpes Simplex Infections - Products under Development by Companies 18
Herpes Simplex Infections - Products under Investigation by Universities/Institutes 19
Herpes Simplex Infections - Companies Involved in Therapeutics Development 20
Sanofi 20
GenVec, Inc. 21
Astellas Pharma Inc. 22
CEL-SCI Corporation 23
Mymetics Corporation 24
NovaBay Pharmaceuticals, Inc. 25
Peregrine Pharmaceuticals, Inc. 26
Oryzon Genomics S.A. 27
Colby Pharmaceutical Company 28
ViroStatics, srl 29
Osel Inc. 30
AlphaVax, Inc. 31
Romark Laboratories, L.C. 32
Chimerix, Inc. 33
NanoBio Corporation 34
Immunovaccine, Inc. 35
Immune Design Corp. 36
Seek 37
Adamis Pharmaceuticals Corporation 38
Vaxart, Inc. 39
Genocea Biosciences, Inc. 40
Pharis Biotec GmbH 41
Profectus BioSciences, Inc. 42
3-V Biosciences, Inc. 43
PaxVax 44
Spider Biotech 45
Kala Pharmaceuticals, Inc. 46
Vaccibody AS 47
Sanofi Pasteur SA 48
Humabs BioMed SA 49
BioApex, s.r.o. 50
Herpes Simplex Infections - Therapeutics Assessment 51
Assessment by Monotherapy Products 51
Assessment by Combination Products 52
Assessment by Target 53
Assessment by Mechanism of Action 55
Assessment by Route of Administration 57
Assessment by Molecule Type 59
Drug Profiles 61
amenamevir - Drug Profile 61
GEN-003 - Drug Profile 62
herpes simplex virus vaccine - Drug Profile 64
HSV-529 - Drug Profile 65
brincidofovir - Drug Profile 67
CEL-1000 - Drug Profile 69
Vaccine for Herpes Simplex Infections - Drug Profile 71
herpes simplex vaccine [HSV-2] - Drug Profile 72
C-31G - Drug Profile 73
Cyanovirin-N for Infectious Disease - Drug Profile 75
GEN-002 - Drug Profile 76
NVC-727 - Drug Profile 77
NVC-638 - Drug Profile 78
NVC-704 - Drug Profile 79
JVRS-100 + Herpes Simplex Virus-2 Vaccine - Drug Profile 80
Drug for Herpes Simplex - Drug Profile 81
PGN-632 - Drug Profile 82
G-103 - Drug Profile 83
GV-2207 - Drug Profile 84
acyclovir - Drug Profile 85
SB-105 - Drug Profile 86
Monoclonal Antibodies for HIV and Herpes Simplex Infections - Drug Profile 87
Synthetic Peptide for Oncology and Infectious Disease - Drug Profile 88
herpes simplex virus vaccine - Drug Profile 89
MB-66 - Drug Profile 90
Small Molecule to Inhibit Fatty Acid Synthase for Viral Infections - Drug Profile 91
BA-368 - Drug Profile 92
HSV-2 Vaccine - Drug Profile 93
Small Molecule Inhibiting Kinases for Viral Infections - Drug Profile 94
mab hu2c - Drug Profile 95
herpes simplex virus vaccine - Drug Profile 96
herpes simplex vaccine - Drug Profile 97
herpes vaccine [HSV-2] - Drug Profile 98
Small Molecules for Respiratory Syncitial Virus and Herpes Simplex Virus Infections - Drug Profile 99
Peptide for Herpes Simplex Infections - Drug Profile 100
Small Molecule to Inhibit LSD-1 For HSV - Drug Profile 101
RC-100b - Drug Profile 102
Monoclonal Antibody for Herpes Simplex Infections - Drug Profile 103
Subunit Vaccine for Herpes Simplex Virus 2 - Drug Profile 104
Small Molecules for Viral Infections - Drug Profile 105
SB105-A10 - Drug Profile 106
Monoclonal Antibody for Herpes Simplex Infections - Drug Profile 108
Labyrinthopeptine A1 - Drug Profile 109
HSV vaccine [HSV1/2 and HSV2] - Drug Profile 110
Small Molecules for Bacterial and Viral Infections - Drug Profile 111
Small Molecule to Inhibit CDK9 for EBV and HSV Infections - Drug Profile 112
Herpes Simplex Infections - Recent Pipeline Updates 113
Herpes Simplex Infections - Dormant Projects 125
Herpes Simplex Infections - Discontinued Products 126
Herpes Simplex Infections - Product Development Milestones 127
Featured News & Press Releases 127
Appendix 136
Methodology 136
Coverage 136
Secondary Research 136
Primary Research 136
Expert Panel Validation 136
Contact Us 137
Disclaimer 137

List of Tables
Number of Products under Development for Herpes Simplex Infections, H2 2014 12
Number of Products under Development for Herpes Simplex Infections - Comparative Analysis, H2 2014 13
Number of Products under Development by Companies, H2 2014 15
Number of Products under Development by Companies, H2 2014 (Contd..1) 16
Number of Products under Investigation by Universities/Institutes, H2 2014 17
Comparative Analysis by Late Stage Development, H2 2014 18
Comparative Analysis by Clinical Stage Development, H2 2014 19
Comparative Analysis by Early Stage Development, H2 2014 20
Products under Development by Companies, H2 2014 21
Products under Investigation by Universities/Institutes, H2 2014 22
Herpes Simplex Infections - Pipeline by Sanofi, H2 2014 23
Herpes Simplex Infections - Pipeline by GenVec, Inc., H2 2014 24
Herpes Simplex Infections - Pipeline by Astellas Pharma Inc., H2 2014 25
Herpes Simplex Infections - Pipeline by CEL-SCI Corporation, H2 2014 26
Herpes Simplex Infections - Pipeline by Mymetics Corporation, H2 2014 27
Herpes Simplex Infections - Pipeline by NovaBay Pharmaceuticals, Inc., H2 2014 28
Herpes Simplex Infections - Pipeline by Peregrine Pharmaceuticals, Inc., H2 2014 29
Herpes Simplex Infections - Pipeline by Oryzon Genomics S.A., H2 2014 30
Herpes Simplex Infections - Pipeline by Colby Pharmaceutical Company, H2 2014 31
Herpes Simplex Infections - Pipeline by ViroStatics, srl, H2 2014 32
Herpes Simplex Infections - Pipeline by Osel Inc., H2 2014 33
Herpes Simplex Infections - Pipeline by AlphaVax, Inc., H2 2014 34
Herpes Simplex Infections - Pipeline by Romark Laboratories, L.C., H2 2014 35
Herpes Simplex Infections - Pipeline by Chimerix, Inc., H2 2014 36
Herpes Simplex Infections - Pipeline by NanoBio Corporation, H2 2014 37
Herpes Simplex Infections - Pipeline by Immunovaccine, Inc., H2 2014 38
Herpes Simplex Infections - Pipeline by Immune Design Corp., H2 2014 39
Herpes Simplex Infections - Pipeline by Seek, H2 2014 40
Herpes Simplex Infections - Pipeline by Adamis Pharmaceuticals Corporation, H2 2014 41
Herpes Simplex Infections - Pipeline by Vaxart, Inc., H2 2014 42
Herpes Simplex Infections - Pipeline by Genocea Biosciences, Inc., H2 2014 43
Herpes Simplex Infections - Pipeline by Pharis Biotec GmbH, H2 2014 44
Herpes Simplex Infections - Pipeline by Profectus BioSciences, Inc., H2 2014 45
Herpes Simplex Infections - Pipeline by 3-V Biosciences, Inc., H2 2014 46
Herpes Simplex Infections - Pipeline by PaxVax, H2 2014 47
Herpes Simplex Infections - Pipeline by Spider Biotech, H2 2014 48
Herpes Simplex Infections - Pipeline by Kala Pharmaceuticals, Inc., H2 2014 49
Herpes Simplex Infections - Pipeline by Vaccibody AS, H2 2014 50
Herpes Simplex Infections - Pipeline by Sanofi Pasteur SA, H2 2014 51
Herpes Simplex Infections - Pipeline by Humabs BioMed SA, H2 2014 52
Herpes Simplex Infections - Pipeline by BioApex, s.r.o., H2 2014 53
Assessment by Monotherapy Products, H2 2014 54
Assessment by Combination Products, H2 2014 55
Number of Products by Stage and Target, H2 2014 57
Number of Products by Stage and Mechanism of Action, H2 2014 59
Number of Products by Stage and Route of Administration, H2 2014 61
Number of Products by Stage and Molecule Type, H2 2014 63
Herpes Simplex Infections Therapeutics - Recent Pipeline Updates, H2 2014 116
Herpes Simplex Infections - Dormant Projects, H2 2014 128
Herpes Simplex Infections - Discontinued Products, H2 2014 129